N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing

Fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] is cytotoxic in many cancer cell types. Studies have shown that elevation of ceramide species plays a role in 4-HPR cytotoxicity. To determine 4-HPR activity in a multidrug-resistant cancer cell line as well as to study ceramide metabolism, MCF-7/AdrR cells (redesignated NCI/ADR-RES) were treated with 4-HPR and sphingolipids were analyzed. TLC analysis of cells radiolabeled with [3H]palmitic acid showed that 4-HPR elicited a dose-responsive increase in radioactivity migrating in the ceramide region of the chromatogram and a decrease in cell viability. Results from liquid chromatography/electrospray tandem mass spectrometry revealed large elevations in dihydroceramides (N-acylsphinganines), but not desaturated ceramides, and large increases in complex dihydrosphingolipids (dihydrosphingomyelins, monohexosyldihydroceramides), sphinganine, and sphinganine 1-phosphate. To test the hypothesis that elevation of sphinganine participates in the cytotoxicity of 4-HPR, cells were treated with the sphingosine kinase inhibitor d-erythro-N,N-dimethylsphingosine (DMS), with and without 4-HPR. After 24 h, the 4-HPR/DMS combination caused a 9-fold increase in sphinganine that was sustained through +48 hours, decreased sphinganine 1-phosphate, and increased cytotoxicity. Increased dihydrosphingolipids and sphinganine were also found in HL-60 leukemia cells and HT-29 colon cancer cells treated with 4-HPR. The 4-HPR/DMS combination elicited increased apoptosis in all three cell lines. We propose that a mechanism of 4-HPR–induced cytotoxicity involves increases in dihydrosphingolipids, and that the synergy between 4-HPR and DMS is associated with large increases in cellular sphinganine. These studies suggest that enhanced clinical efficacy of 4-HPR may be realized through regimens containing agents that modulate sphingoid base metabolism. [Mol Cancer Ther 2008;7(9):2967–76]

[1]  A. Giuliano,et al.  Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. , 2007, Biochimica et biophysica acta.

[2]  S. Groshen,et al.  Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematologic malignancies , 2007 .

[3]  S. Groshen,et al.  High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: A study by the California Cancer Consortium , 2007 .

[4]  A. Bielawska,et al.  Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells* , 2007, Journal of Biological Chemistry.

[5]  Dana Ravid,et al.  A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. , 2007, Cancer letters.

[6]  P. Codogno,et al.  Is Autophagy the Key Mechanism by Which the Sphingolipid Rheostat Controls the Cell Fate Decision? , 2007, Autophagy.

[7]  M. Cabot,et al.  Glycosphingolipids and drug resistance. , 2006, Biochimica et biophysica acta.

[8]  M. Cabot,et al.  Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. , 2006, Biochimica et biophysica acta.

[9]  S. Milstien,et al.  Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. , 2006, Biochimica et biophysica acta.

[10]  G. Reaman,et al.  Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. J. Kim,et al.  Mechanisms of fenretinide-induced apoptosis , 2006, Apoptosis.

[12]  P. Codogno,et al.  Regulation of Autophagy by Sphingosine Kinase 1 and Its Role in Cell Survival during Nutrient Starvation* , 2006, Journal of Biological Chemistry.

[13]  R. Blumenthal,et al.  The clinical potential of sphingolipid-based therapeutics , 2006, Cellular and Molecular Life Sciences CMLS.

[14]  Raymond Sawaya,et al.  The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.

[15]  A. Merrill,et al.  Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. , 2005, Methods.

[16]  Amadeu Llebaria,et al.  Specificity of the Dihydroceramide Desaturase Inhibitor N-[(1R,2S)-2-Hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in Primary Cultured Cerebellar Neurons , 2004, Molecular Pharmacology.

[17]  Daniel J. Klionsky,et al.  Autophagy in Health and Disease: A Double-Edged Sword , 2004, Science.

[18]  F. Rehman,et al.  Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity , 2004, British Journal of Cancer.

[19]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[20]  C. Bauvy,et al.  Ceramide-mediated Macroautophagy Involves Inhibition of Protein Kinase B and Up-regulation of Beclin 1* , 2004, Journal of Biological Chemistry.

[21]  Wei Hu,et al.  Anticancer therapy targeting the apoptotic pathway. , 2003, The Lancet. Oncology.

[22]  M. Cabot,et al.  Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. , 2003, Molecular pharmacology.

[23]  L. Boni,et al.  Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  M. Cabot,et al.  Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. , 2003, Urology.

[25]  J. Kok,et al.  Altered sphingolipid metabolism in multidrug‐resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  R. Kolesnick.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway. , 2002, The Journal of clinical investigation.

[27]  J. Ventura,et al.  Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. , 2002, Biochemical and biophysical research communications.

[28]  Y. Hannun,et al.  Biochemical Mechanisms of the Generation of Endogenous Long Chain Ceramide in Response to Exogenous Short Chain Ceramide in the A549 Human Lung Adenocarcinoma Cell Line , 2002, The Journal of Biological Chemistry.

[29]  Y. Hannun,et al.  Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  S. Di Bartolomeo,et al.  Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells. , 2001, Biochemical and biophysical research communications.

[31]  M. Cabot,et al.  N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. , 2001, Cancer research.

[32]  J. Kok,et al.  The Involvement of Sphingolipids in Multidrug Resistance , 2001, The Journal of Membrane Biology.

[33]  Y. Yun,et al.  Differential effects of fumonisin B1 on cell death in cultured cells: the significance of the elevated sphinganine , 2001, Archives of pharmacal research.

[34]  M. Cabot,et al.  Targeting ceramide metabolism--a strategy for overcoming drug resistance. , 2001, Journal of the National Cancer Institute.

[35]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  M. Cabot,et al.  Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. , 2000, Journal of the National Cancer Institute.

[37]  M. Cabot,et al.  Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. , 1999, Journal of the National Cancer Institute.

[38]  S. Spiegel,et al.  Dual Actions of Sphingosine-1-Phosphate: Extracellular through the Gi-coupled Receptor Edg-1 and Intracellular to Regulate Proliferation and Survival , 1998, The Journal of cell biology.

[39]  A. Merrill,et al.  Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. , 1998, Toxicology and applied pharmacology.

[40]  A. Colell,et al.  Direct Effect of Ceramide on the Mitochondrial Electron Transport Chain Leads to Generation of Reactive Oxygen Species , 1997, The Journal of Biological Chemistry.

[41]  A E Giuliano,et al.  Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells* , 1996, The Journal of Biological Chemistry.

[42]  C. Potten,et al.  Apoptosis and cancer chemotherapy. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[43]  A. Bielawska,et al.  Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. , 1993, The Journal of biological chemistry.

[44]  L. Mariani,et al.  Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. , 1991, European journal of cancer.

[45]  V. Stevens,et al.  Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for an involvement of protein kinase C. , 1990, Biochimica et biophysica acta.

[46]  V. Stevens,et al.  Modulation of retinoic acid-induced differentiation of human leukemia (HL-60) cells by serum factors and sphinganine. , 1990, Cancer research.

[47]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[48]  M. Konopleva,et al.  Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells , 2008, Leukemia.

[49]  R. Kolesnick,et al.  Ceramide and sphingosine 1-phosphate in anti-cancer therapies. , 2003, Cancer treatment and research.

[50]  L. Obeid,et al.  Mechanisms of ceramide-mediated apoptosis. , 1997, Advances in experimental medicine and biology.